- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- quetiapine fumarate, risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,098 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 63
- States / cities
- Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2017–2040
of 9,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
- Interventions
- Finerenone, Sotagliflozin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Portland, Oregon
- Conditions
- High Grade Serous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Upifitimab rilsodotin, Placebo
- Drug · Other
- Lead sponsor
- Mersana Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2, Prediabetic State, Sleep Initiation and Maintenance Disorders
- Interventions
- SHUTi, Patient Education
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 22 Years to 79 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Colorectal Cancer
- Interventions
- Not listed
- Lead sponsor
- Epigenomics, Inc
- Industry
- Eligibility
- 49 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Portland, Oregon
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
- Conditions
- Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
- Interventions
- SGR-1505
- Drug
- Lead sponsor
- Schrödinger, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Itacitinib, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 28 Days to 18 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • Orange, California • Aurora, Colorado + 10 more
- Conditions
- CKD - Chronic Kidney Disease
- Interventions
- Letter Intervention, Letter + Phone Call Intervention:, Augmented usual care
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hepatitis C, Chronic
- Interventions
- Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
- Conditions
- Mesial Temporal Lobe Epilepsy
- Interventions
- NRTX-1001, Sham Comparator
- Biological · Procedure
- Lead sponsor
- Neurona Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2043
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- Postoperative chemotherapy, Perioperative chemotherapy
- Procedure
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 283
- States / cities
- Antioch, California • Duarte, California • Fremont, California + 210 more
- Conditions
- Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
- Interventions
- Eflornithine, Lomustine
- Drug
- Lead sponsor
- Orbus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
- Conditions
- Healthy
- Interventions
- ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay
- Device
- Lead sponsor
- Abbott Diagnostics Division
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41,862 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Lakeland, Florida • St. Petersburg, Florida • Glenview, Illinois + 4 more
- Conditions
- Large B-cell Lymphoma
- Interventions
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide, Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
- Genetic · Drug · Device
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 64
- States / cities
- Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 52 more
- Conditions
- Crohn's Disease
- Interventions
- Alicaforsen
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 24 more
- Conditions
- Sleep Apnea Syndromes, Snoring
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Pomona, California • San Jose, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- Tysabri® (natalizumab)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,096 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Cullman, Georgia + 8 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Aclidinium bromide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 104
- States / cities
- Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 90 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Meniscus Tear
- Interventions
- AM3101, Saline Placebo
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Cleveland, Ohio • Portland, Oregon